Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 7

Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

February 4, 2025

Panelists discuss their optimal strategies for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T in the treatment of relapsed/refractory multiple myeloma (R/R MM).

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

EP. 2: Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

EP. 3: Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma

EP. 4: Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

EP. 5: CAR T and Evolving Treatment Paradigms for Early R/R MM

EP. 6: Expert Perspectives: Referrals and Present Challenges with CAR T for Early R/R MM

Now Viewing

EP. 7: Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

EP. 8: Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

EP. 9: CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial

EP. 10: Weighing CAR T Toxicity Profiles in Early R/R MM

EP. 11: The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma

EP. 12: Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma

EP. 13: Recent Insights Into Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

EP. 14: Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma

EP. 15: Future Treatment Considerations for Multiple Myeloma

Video content above is prompted by the following:

In preparing patients to receive CAR T, what is your optimal strategy for bridging therapy?